10x Genomics (TXG) Cash & Current Investments (2018 - 2026)

10x Genomics (TXG) has 9 years of Cash & Current Investments data on file, last reported at $539.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 26.46% year-over-year to $539.8 million; the trailing twelve-month figure through Mar 2026 stood at $539.8 million (up 26.46% YoY), and the FY2025 full-year result was $523.4 million, up 33.05% from the prior year.
• Cash & Current Investments advanced to $539.8 million in Q1 2026, from $523.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $539.8 million in Q1 2026 to a low of $222.4 million in Q4 2022.
• A 5-year average of $406.2 million and a median of $398.2 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments plunged 62.21% in 2022 and soared 74.79% in 2023, its largest moves.
• Tracing TXG's Cash & Current Investments over 5 years: stood at $222.4 million in 2022, then soared by 74.79% to $388.7 million in 2023, then climbed by 1.21% to $393.4 million in 2024, then surged by 33.05% to $523.4 million in 2025, then grew by 3.14% to $539.8 million in 2026.
• Business Quant data shows TXG's Cash & Current Investments at $539.8 million in Q1 2026, $523.4 million in Q4 2025, and $482.1 million in Q3 2025.